Riskpilot← Back to searchSign inGet full accessChemalys Scientific AB
ABActiveOrg 5566787510Torsvägen 35Other software publishing · NACE 5829Est. 20051 employees
Revenue 2024
SEK 183K
-17% vs 2023
EBITDA margin
-12.7%
+72% vs 2023
Equity ratio
84.3%
Financial strength
Net profit 2024
SEK -23K
+72% vs 2023
| Revenue | SEK 183K | -17% |
| EBITDA | SEK -23K | +72% |
| Net profit | SEK -23K | +72% |
| Total assets | SEK 112K | -28% |
| Equity | SEK 95K | -20% |
| Employees | 1 | — |
Legal name
Chemalys Scientific AB
Org number
5566787510
Legal form
Aktiebolag
NACE code
5829 · Other software publishing
Founded
1 april 2005
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall inom området analytisk kemi och bioteknik bedriva konsult- och utbildningsverksamhet, försäljning-support och installation av programvara och teknisk utrustning, samt idka därmed förenlig verksamhet. Dessutom skall bolaget förvalta fast och lös egendom företrädesvis aktier och andra värdepapper samt bedriva därmed förenlig verksamhet.
Address
Torsvägen 35
Phone
+4687412074
Email
jan.nordin@chemalys.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 343 | 234 | 330 | 220 | 183 |
| Staff expenses | — | — | — | −133 | −46 |
| EBITDA | −32 | 1 | −37 | −82 | −23 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −32 | 1 | −37 | −82 | −23 |
| Net financials | 1 | — | — | 0 | 0 |
| Profit before tax | −31 | 1 | −37 | −81 | −23 |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | −31 | 1 | −37 | −81 | −23 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 326 | 287 | 213 | 157 | 112 |
| Equity | 235 | 236 | 199 | 118 | 95 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 91 | 51 | 14 | 39 | 18 |
| Total debt | 91 | 51 | 14 | 39 | 18 |
EBITDA margin
-12.7%
This company
15.8%
Market median
-180% vs market
20202024
Equity ratio
84.3%
This company
38.2%
Market median
+121% vs market
20202024
Return on equity
-24.3%
This company
18.4%
Market median
-232% vs market
20202024
Net profit margin
-12.5%
This company
8.1%
Market median
-254% vs market
20202024
Asset turnover
1.63×
This company
1.12×
Market median
+46% vs market
20202024
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JI Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
HH Audit | Audit | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Chemalys Scientific AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Henric Larsolle | Audit | 0 companies |
| Jan Ingvar Nordin | Chief Executive Officer | 0 companies |
| Karl Henrik Nordin Djurstedt | Deputy Board Member | 0 companies |
| Ulf Anton Ingvar Nordin | Deputy Board Member | 0 companies |